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ABSTRACT

Objective We investigated the relationships of maternal
circulating individual free fatty acids (FFA) with insulin
resistance, insulin secretion and inflammatory biomarkers
during mid-pregnancy.
Research design and methods The data were drawn
from a prospective cohort of generally healthy pregnant
women (n=1368, African-American 36%, Hispanic
48%, Caucasian 16%) in Camden, NJ. We quantitatively
determined 11 FFAs, seven cytokine/adipokine,
homeostatic model assessment of insulin resistance
(HOMA-IR) and C-peptide levels from the fasting blood
samples that were collected at 16 weeks of gestation.
Multivariate analyses were performed along with separate
analyses for each individual FFA.
Results High HOMA-IR (p<0.001) and C-peptide
(p<0.0001) levels were positively associated with
a twofold to fourfold increased risk for developing
gestational diabetes mellitus (GDM). Negative relationships
were found with specific FFAs (molecular percentage,
palmitoleic, oleic, linolenic, myristic acids) and HOMA-IR
and C-peptide levels (p<0.01 to p<0.0001). In contrast,
palmitic, stearic, arachidonic, dihomo-γ-linolenic (DGLA)
and docosahexaenoic acids were positively associated
with HOMA-IR and C-peptide (p<0.01 to p<0.0001). The
individual FFAs also predicted cytokine/adipokine levels.
For example, women who had elevated DGLA (highest
quartile) were twice as (adjusted OR 2.06, 95% CI 1.42 to
2.98) likely to have higher interleukin (IL)-8 (p<0.0001)
levels. Conversely, women with high palmitoleic, oleic, and
linolenic acid levels had reduced odds (≥2-fold, p<0.01 to
p<0.001) for having higher IL-8, IL-6 or tumor necrosis
factor-alpha levels.
Conclusion Our results suggest that maternal individual
FFAs uniquely affect insulin resistance and secretion. The
effects are either direct or indirect via modulation of the
inflammatory response. Modifying the composition of FFAs
may help in reducing the risk of GDM.

Introduction
Resistance to the actions of insulin on glucose
and fat metabolism has been observed in
normal pregnancy, particularly during late
gestation.1 2 Excessive insulin resistance

Significance of this study
What is already known about this subject?
►► Previous studies were limited to the relation of total

concentrations of free fatty acids (FFAs) with insulin
resistance/secretion in pregnant women with and
without gestational diabetes mellitus (GDM).
►► How specific individual FFAs are involved in the
regulation of glucose homeostasis and modulate
inflammatory response in normal pregnancy and
in women prior to the diagnosis of GDM remains
uncertain.

What are the new findings?
►► In this prospective and well characterized cohort

of young pregnant women, we show that specific individual FFAs have strong, but opposite effects on insulin resistance and insulin secretion by
mid-pregnancy.
►► Different associations between specific FFAs and
inflammatory biomarkers (cytokine/adipokine) were
also observed.

How might these results change the focus of
research or clinical practice?
►► Our data suggest that individual FFAs have unique

metabolic impacts in healthy pregnant women and
in women prior to the diagnosis of GDM.
►► The recognition and modification of circulating FFAs
composition could be important for reducing the risk
of GDM and other pregnancy complications related
to subclinical inflammation and insulin resistance.

(IR) and significant β-cell dysfunction are
key components for the development of
gestational diabetes mellitus (GDM).3–5
How IR develops during pregnancy is not
fully understood. Circulating free fatty acids
(FFA) have been recognized as one of the
most important factors that contribute to IR
and also alter insulin secretion.1 6 7 Previous
studies by Boden and Chen demonstrated
that experimentally created acute elevations
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in circulating total FFA concentration cause increases in
IR in healthy non-pregnant subjects, and type 2 diabetes
mellitus (T2DM) and in pregnant women with and
without GDM.1 7 8 Elevated total FFA levels significantly
increase insulin secretion in normal subjects, but not in
T2DM and GDM; here insulin secretion is defective.1 6–8
Thus, the relationship of the individual FFAs, instead of
total FFA, to IR and insulin secretion in human pregnancy needs further investigation.
Strong evidence indicates that chronic low-grade
inflammation which is characterized by increased circulating cytokine levels is another key factor associated
with IR.4 9 FFAs have emerged as an important link
for explaining inflammatory-related conditions.10–12
Increased total FFA levels induced whole body proinflammatory responses and impaired endothelial function in
non-pregnant healthy subjects.9 13 Supplementation with
n-3 fatty acids (FA) in obese pregnant women resulted in
decreased cytokine levels in both placenta and adipose
tissues.14 Although in vitro studies have reported that
individual FAs modulate the inflammatory response
in cultured cells,15 16 results are equivocal. Whether
maternal individual FFAs affect inflammatory cytokine
levels differently in human pregnancy is not known.
The purpose of the present study was to examine the
relationships of individual FFAs with measures of IR
(homeostatic model assessment of insulin resistance,
HOMA-IR), insulin secretion indicated by C-peptide
level, and inflammatory biomarkers from the Camden
Study, a well-characterized prospective cohort of generally healthy pregnant women at high risk of adverse
maternal-fetal outcomes. We hypothesized that individual
FFAs have (1) different relationships with IR and insulin
secretion and (2) different associations with inflammatory cytokine/adipokine levels in human pregnancy.
Research design and methods
Study design and population
The data were collected as part of the Camden Study,
a prospective cohort study of maternal nutrition and
pregnancy outcome in young, generally healthy women
residing in one of the poorest cities in the continental
United States.17 18 The study was conducted in the Osborn
Family Health Center at Our Lady of Lourdes Hospital
in Camden, NJ. Informed written consent was obtained
from each participant after explanation of the nature
and purpose of the study.
Study participants were enrolled between October
1996 and June 2006 for prenatal care. A total of 3.5% of
the women who had serious non-obstetric problems (eg,
lupus, type 1 or 2 diabetes, seizure disorders, malignancies, acute or chronic liver disease, drug or alcohol abuse
and psychiatric problems) were found not to be eligible
at screening. Eighty percent of the patients who were
eligible agreed to participate in this study. Of the 1703
pregnant women who had all measurements assayed,
we also excluded participants who were diagnosed with
2

pre-eclampsia (n=186) or delivered a preterm infant
(n=149) since both conditions are potentially associated
with metabolic disturbance and/or increased inflammation.19–21 Twenty-five women who were diagnosed with
GDM and also had complication of pre-eclampsia (n=13)
or preterm delivery (n=12) were not excluded. A final
group of 1368 women were included in this analysis.
Data collection
Data of socioeconomic, demographic and lifestyle characteristics were obtained by interview at entry to care
(13.4±5.2 weeks of gestation, mean±SD), and updated at
20 and 28 weeks of gestation. Ethnicity was self-defined.
Gestational duration was assessed with an algorithm based
on a participant’s last normal menstrual period confirmed
or modified by early ultrasound. Body mass index (BMI)
was computed based on self-reported pregravid weight
and measured height at entry to prenatal care (kg/m2).
Diagnosis of GDM and definition of normal controls
The diagnosis of GDM was made by a two-step approach.
Patients were initially screened by a 50 g oral glucose
challenge test at the 24–28 weeks of gestation. A 100 g
oral glucose tolerance test (OGTT) was performed on
that subset of women exceeding the glucose threshold
value (>140 mg/dL at 1 hour). The diagnostic criteria
for GDM were based on the Carpenter/Coustan conversion as recommended by the American Diabetes Association.22 Participants with a normal glucose screen test were
defined as controls.
Sample collection and analytical procedures
Fasting blood samples (>8 hours) collected at entry to
care (15.8±5.2 weeks of gestation) were refrigerated and
centrifuged at 4°C. The serum and plasma samples were
aliquoted and stored at –70°C until assayed.
Measurement of FFAs
We measured the plasma concentration and relative
abundance of 11 FFAs (myristic, palmitic, stearic, palmitoleic, oleic, linoleic, α-linolenic, dihomo-γ-linolenic
(DGLA), arachidonic, eicosapentaenoic (EPA) and docosahexaenoic (DHA) acids). Total lipids were extracted by
a modified Folch method and analyzed by gas chromatography/mass spectrometry (Agilent Technologies 5973
MS/6890 GC, Santa Clara, CA) as described previously.23
An internal standard heptadecanoic acid (C17:0) was
added to each sample before the extraction of FAs to
identify the FFA fraction from other lipid classes which
was separated by thin layer chromatography. A nitroterephthalic acid-modified polyethylene glycol capillary
column (ZB-FFAP, Phenomenex, Torrance, CA) was
used. Peak retention times were identified by injecting
known standards (Sigma-Aldrich, Louis, MO). The precision and reproducibility was monitored by the analysis of
reinjection on the same samples and the samples from
different batches.
The peak area of FFA was identified as the percentage
of total area under the peaks and absolute concentration
BMJ Open Diab Res Care 2019;7:e000632. doi:10.1136/bmjdrc-2018-000632
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of FFA was quantified by multiplying each individual
FFA in relative value (%) by the total FFA concentration
(μmol/L) determined by an enzymatic assay kit (Wako
Chemicals USA, Richmond, VA).

to calculate the total daily intake of energy, carbohydrate,
protein, total fat, individual FAs, saturated FA (SFA),
monounsaturated FA and polyunsaturated FA (PUFA)
accordingly.

Assays of cytokine and adipokine
Cytokines (interleukin (IL)-6, IL-8, IL-10, tumor necrosis
factor alpha (TNF-α) and granulocyte-macrophage colony-stimulating factor) and adipokines (adiponectin and
resistin) were analyzed by two panels using the Luminex
xMAP technology (Luminex, Austin, TX) on the MagPix
system. Serum cytokine concentrations were determined
by the human high sensitivity T-cell 5-plex magnetic bead
panel and adipokines were determined by the human
adipokine 2-plex magnetic bead panel (EMD Millipore,
Billerica, MA). According to the manufacturing protocol,
there was no or negligible cross-reactivity between the
antibodies for an analyte and any of the other analytes
in each of the panels. The average intracoefficient variation (CV) was 5.5% (range 4.6%–7.0%) and the average
inter-CV was 11.2% (range 8.2%–13.2%) for cytokines.
The intra-CV was 4.4% and 5.5%, the inter-CV was 10.1%
and 11.3% for adiponectin and resistin, respectively. All
analyses were performed according to the manufactures’
protocols and were done in duplicate. The concentrations were calculated from best fit standard curves generated from calibrators for each analyte in each assay by
Milliplex Analyst V.5.1.

Statistical analysis
Parametric statistics were calculated for the continuous
variables, and χ2 tests for independence were used for
the categorical variables. Log10 transformations were
performed if the data were positively and highly skewed.
Multiple linear regression analyses were used to examine
the relationships of individual FFAs (expressed as molecular percentage, %) with the continuous outcome
variables (HOMA-IR and C-peptide level). Separate
regression models were employed to estimate the relationships of each of the independent variables with the
outcome variables. The same types of analyses were also
performed with the women who were diagnosed with
GDM during later gestation and in normal controls
(online supplementary tables 1 and 2). Multiple logistic
regressions were performed to estimate the ORs and
95% confidence intervals (CI) for the elevated levels of
the glucose metabolism parameters (≥median level) with
GDM at entry (prior to the clinical diagnosis of GDM).
We also conducted multiple polytomous logistic regression analyses to estimate the associations of the elevated
individual FFAs with the cytokine/adipokine levels. This is
an extension of traditional logistic regression in multiple
levels of an outcome variable that are all adjusted so that
the ORs are estimated in the same model. The frequency
distributions of the FFAs (%) were divided into quartiles,
and logistic regression was used to estimate the OR of
high (top quartile) FFAs with cytokine/adipokine levels
in each quartile using the lowest quartile as the reference
category. The linear trends of specific FFAs across the
quartiles of cytokine/adipokine were also tested.
In order to examine the relation between dietary and
circulating FFAs, we correlated (Pearson’s r) plasma individual FFA (molecular %) with the corresponding dietary
FA intake (as % of total fat intake) adjusted for energy
intake.
All multivariable analyses were also conducted
controlling for potential confounding variables which
included maternal BMI, age, parity, cigarette smoking,
and ethnicity. All of the levels of significance were two
sided, and p<0.05 was considered to be the lowest level
of acceptable statistical significance. All of the statistical
analyses were performed with SAS V.9.4 (SAS Institute).

Parameters of glucose and insulin homeostasis
Fasting plasma glucose was measured with the glucose
oxidase method (Sigma Diagnostics, St Louis, MO) on
a Multiscan analyzer (BioTek, Winooski, VT). Serum
insulin was determined by radioimmunoassay (RIA)
using a kit with a specific antibody that cross-reacts only
minimally (<0.2%) with proinsulin and has a high sensitivity (2 mU/mL or 12 pmol/L). Plasma C-peptide was
determined by an RIA kit with high sensitivity (0.1 ng/
mL or 0.033 nmol/L) and low cross activity to proinsulin (<4%) (Linco, St Charles, MO). The intra-CV and
inter-CV were 3.3% and 6.1% for C-peptide, 4.9% and
7.2% for insulin, 3.3% and 5.3% for glucose. We used
C-peptide concentration as an indicator of insulin secretion because it is cosecreted on an equimolar basis from
the β-cell with insulin and is not extracted or metabolized by the liver.3 18 HOMA-IR was computed as index
of IR.24 25
Dietary data
A 24 hours’ recall of the previous day’s diet was obtained
at entry to care, week 20 and 28 gestation processed with
databases from the Campbell Institute of Research and
Technology (Campbell Soup Company) in Camden as
described previously.23 The database generates data for
more than 70 nutrients and 19 FAs using the US Department of Agriculture Nutrient Database for Standard
Reference and the Continuing Survey of Food Intakes by
Individuals. The mean of three 24-hour recalls was used
BMJ Open Diab Res Care 2019;7:e000632. doi:10.1136/bmjdrc-2018-000632

Results
The characteristics of the women at entry (~16 weeks’
gestation) are shown in table 1. As expected, women who
developed GDM during late gestation were older and
had higher pre-pregnant BMI (p<0.0001). There were
more Hispanic and fewer African-American women in
the GDM group (p<0.001). The mean gestational age at
blood sampling, parity and cigarette smoking were not
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Table 1 Characteristics of study participants
All
Characteristic participants GDM

Normal
controls

n
Age (year)

1368
22.08±5.24

81
26.01±6.05

1287
21.90±5.03*

Pre-pregnant
BMI (kg/m2)

25.73±6.22

30.08±6.42

25.37±6.21*

Obesity

250 (18.27)

35 (43.21)

215 (17.92)*

Gestational
age at blood
sampling
(weeks)

15.79±5.24

16.74±5.19

15.72±5.21

Nulliparas

516 (37.72)

29 (35.80)

487 (37.83)

 Hispanic

656 (47.66)

47 (58.02)

609 (47.37)

 AfricanAmerican

490 (35.81)

14 (17.28)

476 (36.98)

 Caucasian
and other

222 (16.22)

20 (24.69)

 202 (15.67)†

Cigarette
smoking

260 (19.00)

17 (20.99)

243 (18.89)

Plasma
glucose
(mmol/L)

4.39±0.02

4.98±0.09

4.34±0.02*

Serum insulin
(pmol/L)

129.73±2.43 161.82±9.79 127.79±2.78†

Plasma
C-peptide
(nmol/L)
HOMA-IR

0.74±0.02

1.20±0.06

0.71±0.02*

3.75±0.08

4.99±0.32

3.67±0.08*

Ethnicity

Data are mean±SD for continuous variables and n (%) for
categorical variables.
Fasting plasma glucose, insulin, C-peptide and HOMA-IR
(means±SE) were adjusted for maternal age, pre-pregnant BMI,
and gestational age at blood sampling.
*P<0.0001 versus GDM.
†P<0.001 versus GDM.
.BMI, body mass index; GDM, gestational diabetes mellitus;
HOMA-IR, homeostatic model assessment of insulin resistance.

significantly different between the GDM women and
normal controls (p>0.05 for each). The concentrations
of fasting plasma glucose, C-peptide, serum insulin and
HOMA-IR were significantly higher in the GDM women
than in the normal controls (p<0.001 to p<0.0001 for
each).
Further analysis by multiple logistic regressions showed
that elevated (≥median entry level) glucose (≥4.38
mmol/L) (adjusted OR (AOR) 2.15, 95% CI 1.30 to
3.56), insulin (≥99.73 pmol/L, AOR 2.49, 95% CI 1.41
to 4.40), C-peptide (≥0.54 nmol/L, AOR 4.43, 95% CI
2.25 to 8.72) and HOMA-IR (≥2.75, AOR 2.71, 95% CI
1.51 to 4.86) were significantly associated with increased
risk for the subsequent development of GDM (p<0.01 to
p<0.0001 for each).
4

Individual FFAs with HOMA-IR and C-peptide
The HOMA-IR and C-peptide levels were regressed on
the linear combination of the potential confounding
variables (age, pre-pregnant BMI, cigarette smoking,
ethnicity and parity) in multiple regression analyses. The
estimated regression coefficients for the multiple models
are presented in table 2. There were significant negative
relationships of several individual FFAs with HOMA-IR (β
coefficient was −0.666, –0.100, −1.317 and −0.309 for 1%
increases in palmitoleic or oleic or α-linolenic or myristic
acids, respectively, p<0.01 to p<0.0001 for each). Inverse
relations were also found with respect to C-peptide (β
coefficient was −0.457, –0.069, −0.984 and −0.211 ng/
mL C-peptide for 1% increases in palmitoleic or oleic
or α-linolenic or myristic acids, respectively, p<0.001 to
p<0.0001 for each).
In contrast, significant positive associations of several
FFAs with HOMA-IR were observed (β coefficient was
0.065, 0.084, 0.778 and 0.269 for palmitic, stearic, DGLA,
and arachidonic acids, respectively, p<0.001 to p<0.0001
for each); similar relationships were found with C-peptide (p<0.0001 for each). There was no significant association of linoleic acid and EPA with HOMA-IR. EPA and
DHA were both positively related to C-peptide (p<0.001
and p<0.0001).
Separate analyses were performed for women who
subsequently developed GDM and the normal controls.
The results from the normal controls were identical to
those for all participants (online supplementary table 1).
Similar results were also found for the GDM women, but
the magnitude of these relationships was not statistically
significant (online supplementary table 2). The lack of
significance most likely was probably attributable to the
small sample size of GDM group.
The trends of relationships (positive and negative)
between individual FFAs and HOMA-IR or C-peptide in
non-GDM women who complicated with pre-eclampsia
and preterm delivery are similar to those shown with
GDM and non-GDM normal controls, but significant
association was only found in palmitoleic acid (p<0.01) in
women with preterm delivery; the association was significant in palmitoleic, oleic, α-linolenic and stearic acids in
women with pre-eclampsia (p<0.05 to p<0.001, data not
shown).
Individual FFAs and inflammatory biomarkers
A summary for the FFAs, which were consistently showing
linear associations with at least two cytokines/adipokines,
is presented in table 3. Elevated individual FFAs (the
highest quartile vs other quartiles pooled) were associated with inflammatory biomarkers in opposite directions
(p for trend <0.05 to <0.0001 for each). Significant negative relationships were found for myristic, palmitoleic,
linolenic and oleic acids. For example, women with
higher (highest quartile) palmitoleic acid levels relative
to the other quartiles had a 2.7-fold significant decrease
for having a high IL-8 level (highest quartile vs lowest
quartile, 15.1% vs 31.4%, AOR was 0.36, 95% CI 0.24 to
BMJ Open Diab Res Care 2019;7:e000632. doi:10.1136/bmjdrc-2018-000632
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Table 2 Association of individual FFAs with HOMA-IR and C-peptide concentration
Independent variable
FFAs

Dependent variable
Molecular % (mean±SD)

HOMA-IR

P value

β±SE

C-peptide (ng/mL)

P value

β±SE

Palmitoleic acid (16:1)
Oleic acid (18:1)

2.58±1.22
26.37±7.42

−0.666±0.070
−0.100±0.011

<0.001
<0.0001

−0.457±0.044
−0.069±0.007

<0.0001
<0.0001

Linoleic acid (18:2)

15.53±4.94

−0.031±0.017

NS

−0.022±0.011

<0.05

α-Linolenic acid (18:3)

0.60±0.27

−1.317±0.318

<0.0001

−0.984±0.200

<0.0001

Myristic acid (14:0)

1.91±0.85

−0.309±0.101

<0.01

−0.211±0.064

<0.001

Palmitic acid (16:0)

34.33±7.94

0.065±0.010

<0.0001

0.040±0.007

<0.0001

Stearic acid (18:0)

14.45±5.32

0.084±0.016

<0.001

0.059±0.010

<0.0001

DGLA (20:3)

1.20±0.75

0.778±0.108

<0.0001

0.677±0.067

<0.0001

Arachidonic acid (20:4)

2.02±1.22

0.269±0.069

<0.0001

0.229±0.043

<0.0001

EPA (20:5)
DHA (22:6)

0.15±0.31
0.89±0.55

0.290±0.266
0.303±0.152

NS
<0.05

0.557±0.168
0.410±0.095

<0.001
<0.0001

Models were adjusted for maternal age, pre-pregnant body mass index (BMI), parity, ethnicity and cigarette smoking. Separate model was
performed for each independent variable with HOMA-IR or C-peptide level.
DGLA, dihomo-γ-linolenic acid; DHA, docosahexaenoic acid;EPA, eicosapentaenoic acid; FFA, free fatty acid; HOMA-IR, homeostatic model
assessment of insulin resistance;.NS, not significant.

0.55, p for trend <0.0001). For myristic acid, the AOR was
0.37 (95% CI 0.25 to 0.54). Similar results were found
for the same group of FFAs with IL-6, TNF-α or resistin.
Opposite relationships were found with respect to DGLA,
palmitic acid and EPA (table 3). For example, having a
high DGLA predicted a twofold increase in the odds of
having a high IL-8 (AOR 2.06, 95% CI 1.42 to 2.98, p for
trend <0.0001). However, no significant relationships of
stearic, linoleic, and DHA with cytokine/adipokine levels
were observed. Arachidonic acid was only associated with
one marker of cytokine/adipokine, TNF-α (AOR 1.72,
95% CI 1.20 to 2.46), which is not listed in table 3.
For the FFAs that had significant linear relationships
with cytokine/adipokine levels, we compared the effect
of higher FFAs on each of the quartile of cytokine/
adipokine levels (using the lowest quartile as reference)
(figure 1). For the negative associations of linolenic and
myristic acids, there was a trend for decreasing AORs
across the IL-6, IL-8 and TNF-α quartiles. For the positive associations of DGLA and palmitic acid, the AORs
increased across the quartiles for IL-8, TNF-α, and
resistin.
We did not observe any association of FFAs (in molecular percentage) to adiponectin. Adiponectin was
inversely correlated with maternal pre-pregnant BMI
(Pearson’s r=−0.283, p<0.0001), HOMA-IR (β coefficient −0.616, p<0.001) and C-peptide (β coefficient
–0.567, p<0.0001). In addition, the adiponectin levels
were negatively correlated with the absolute concentrations (μmol/L) of palmitic acid (p<0.0001), stearic
acids (p<0.01), DGLA (p<0.05) and total FFA (p<0.01).
Compared with the lowest quartile, the highest quartile
of palmitic acid was associated with decreasing levels of
adiponectin (AOR 0.66, 95% CI 0.46 to 0.94) when BMI
BMJ Open Diab Res Care 2019;7:e000632. doi:10.1136/bmjdrc-2018-000632

was not controlled for. This finding was not significant
after BMI was controlled for.
Individual FFAs and dietary fat intake
We correlated plasma individual FFA (molecular %) with
the corresponding dietary FA intake (as % of total fat
intake) adjusted for energy intake. Plasma myristic acid
was minimally correlated with dietary intakes of myristic
acid (r=0.100, p<0.0001), total fat (r=−0.07, p<0.05) and
total PUFAs (r=−0.116, p<0.001). The correlations with
other FAs were non-significant and negligible.
Conclusions
In this prospective cohort of young pregnant women,
we have shown different associations of circulating individual FFAs with measurements of IR and secretion. Most
importantly, opposite relationships between specific FFAs
and inflammatory biomarkers (cytokine/adipokine)
were also observed. The results indicate that individual
FFAs have unique metabolic impacts by mid-pregnancy.
Markers identifying GDM risk
There has been a lack of consistency in the identification
of markers that predict GDM.26–28 We found that higher
HOMA-IR or C-peptide or insulin or glucose concentration determined at ~16 weeks’ gestation was associated
with 2.7-fold to 4.4-fold increased risk for developing
GDM independent of several traditional risk factors,
including maternal age and BMI. Recently, in a secondary
analysis of case–control study, Hinkle et al reported that
elevated HbA1c levels at 8–13 weeks’ gestation were associated with GDM.26 Another study reported that HOMA-IR
at week 7–12 gestation was associated with GDM.27 Thus,
impaired glucose homeostasis seems to occur before
5
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Table 3 Association of elevated individual FFAs (molecular percentage, %) with inflammatory biomarkers
High FFA and cytokine/adipokine*

Quartile 1
n=338

Quartile 2
n=349

Quartile 3
n=343

Quartile 4
n=338

Myristic acid (≥2.28 vs <2.28)

%

%

%

%

 IL-6

30.9

27.5

21.6

 IL-8

35.8

27.1

20.6

 TNF-α

33.4

23.8

 Resistin

19.3

 IL-6
 IL-8

AOR (95% CI)†

P for trend

20.1

0.58 (0.40 to 0.83)

<0.0001

16.5

0.37 (0.25 to 0.54)

<0.0001

26.9

15.9

0.40 (0.27 to 0.59)

<0.0001

27.5

26.5

26.2

1.30 (0.89 to 1.88)

NS

24.2

28.3

27.1

20.4

0.67 (0.46 to 0.98)

<0.05

31.4

26.9

26.6

15.1

0.36 (0.24 to 0.55)

<0.0001

 TNF-α

22.6

27.3

34.1

16.0

0.56 (0.38 to 0.84)

<0.05

 Resistin

29.2

25.4

24.5

20.9

0.55 (0.38 to 0.80)

<0.001

 IL-6

31.3

23.0

26.2

19.5

0.50 (0.35 to 0.72)

<0.001

 IL-8

28.6

25.4

25.1

20.8

0.67 (0.47 to 0.96)

<0.05

 TNF-α

27.8

25.7

27.8

18.8

0.62 (0.43 to 0.89)

<0.05

 Resistin

23.9

27.1

24.1

25.0

0.91 (0.64 to 1.29)

NS

 IL-6

24.1

24.9

29.8

21.2

0.75 (0.52 to 1.09)

NS

 IL-8

28.7

27.5

26.9

16.8

0.50 (0.34 to 0.73)

<0.001

 TNF-α

25.8

25.5

30.1

18.6

0.62 (0.43 to 0.90)

<0.05

 Resistin

26.7

28.6

26.4

18.6

0.52 (0.36 to 0.76)

<0.001

 IL-6

23.5

25.5

25.8

25.2

1.08 (0.76 to 1.55)

NS

 IL-8

17.9

23.2

29.1

29.7

2.06 (1.42 to 2.98)

<0.0001

 TNF-α

19.5

25.1

25.7

29.8

1.83 (1.28 to 2.63)

<0.01

 Resistin

20.8

23.2

30.5

25.5

1.22 (0.85 to 1.76)

NS

 IL-6

22.5

24.4

23.8

29.5

1.49 (1.05 to 2.12)

<0.05

 IL-8

23.7

22.2

23.7

30.3

1.51 (1.07 to 2.15)

<0.05

 TNF-α

25.5

22.4

23.6

28.5

1.22 (0.86 to 1.73)

NS

 Resistin

17.3

24.1

27.1

31.6

2.20 (1.40 to 2.92)

<0.0001

 IL-6

22.7

23.9

24.5

29.0

1.47 (1.03 to 2.11)

<0.05

 IL-8

21.2

23.7

24.9

30.2

1.76 (1.22 to 2.54)

<0.01

 TNF-α

23.4

25.9

24.9

25.9

1.26 (0.87 to 1.81)

NS

 Resistin

18.7

26.6

27.8

26.9

1.34 (0.92 to 1.95)

NS

Palmitoleic acid (≥3.09 vs <3.09)

α-Linolenic acid (≥0.71 vs <0.71)

Oleic acid (≥30.58 vs <30.58)

DGLA (≥1.73 vs <1.73)

Palmitic acid (≥37.56 vs <37.56)

EPA (≥0.16 vs <0.16)

*High FFA was defined as the highest quartile of FFA.
†Models were adjusted for maternal age, pre-pregnant body mass index (BMI), parity, ethnicity and cigarette smoking. AOR was estimated for
patients who were in the highest quartile of FFA versus other quartiles pooled, association with inflammatory biomarkers in the top quartile using the
lowest quartile as reference.
AOR, adjusted OR;DGLA, dihomo-γ-linolenic acid; EPA, eicosapentaenoic acid; FFA, free fatty acid; IL, interleukin; NS, not significant; TNF-α, tumor
necrosis factor alpha;

the third trimester; our findings confirm that simple
measurements may be useful for earlier identification of
some women at risk for GDM.
Individual FFAs are associated with IR and insulin secretion
differently
A particularly interesting finding in the present study
was that specific individual fasting FFAs have large, but
opposite effects on IR and C-peptide by mid-pregnancy
6

(table 2). The strongest negative relationship was for the
essential FA, α-linolenic acid, whereas DGLA, an endogenously produced n-6 FA, was one of the most positive
correlates to HOMA-IR. Similar results were observed for
the FFAs and C-peptide.
Previous studies were limited to the relation of total
FFA concentration with IR/secretion. Elevation in plasma
total FFAs by infusion of lipid and heparin in healthy
BMJ Open Diab Res Care 2019;7:e000632. doi:10.1136/bmjdrc-2018-000632
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Figure 1 Linear associations of specific FFAs with inflammatory biomarkers. Square markers indicate adjusted ORs
(AOR) which were estimated for patients who were in the highest quartile of FFA (vs other quartiles pooled), association
with inflammatory biomarkers (comparing the quartiles 2–4 to the lowest quartile). Error bars indicate 95% CI. Models were
adjusted for maternal age, pre-pregnant body mass index (BMI), parity, ethnicity and cigarette smoking. Separate models
were performed for each FFA with each of the cytokines/adipokines. DGLA, dihomo-γ-linolenic acid; FFA, free fatty acid; IL,
interleukin; TNF, tumor necrosis factor.

subjects, patients with type 2 diabetes, or pregnant
women with and without GDM caused IR by reducing
insulin-stimulated glucose uptake.6–9 Increased total FFA
level also has a role as an insulin secretagogue in patients
with diabetes and healthy individuals.5 6 Our findings
support FFAs having significant relationships with IR and
insulin secretion, and indicate that individual FFAs are
differentially associated with IR and insulin secretion.
FAs have an important role in the regulation of insulin
homeostasis. In a prospective cohort of American
Indians, Lemaitre et al have shown that higher plasma
level of ceramides or higher sphingomyelins (the sphingolipids species) with SFAs, such as palmitic acid, have
different associations with fasting insulin, HOMA-IR or
HOMA β-cell function.25
BMJ Open Diab Res Care 2019;7:e000632. doi:10.1136/bmjdrc-2018-000632

We found that higher myristic acid, an SFA, was negatively correlated with having favorable relationships with
both HOMA-IR and inflammation (tables 2 and 3). In
non-pregnancy studies, serum myristic acid has positive
or an unfavorable association with subclinical inflammation and with increased risk of T2DM.10 29 For unknown
reasons, our results are contrary to previous observations
in the literature. Additional studies are needed to understand the underlying mechanisms.
Individual FFAs are associated with inflammatory cytokine/
adipokine differently
Another significant finding from the current study was that
elevated individual FFAs were significantly associated with
several major inflammatory markers, including IL-6, IL-8,
7
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and TNF-α and resistin, in different directions (table 3).
Inflammation is a widely known contributor linked to
increased IR.9 11 12 15 30 However, little is known about the
effects of individual FFAs as modulators of inflammation
during pregnancy.
Many studies have reported significant effects for total
FFA levels and/or n-3 FAs in inflammation.9 14 31 Acute
increases in total FFA concentrations induce intracellular
and total cellular inflammation in healthy subjects.9 Supplementation of n-3 FAs (EPA and DHA) in non-pregnancies
reduces blood levels of inflammatory markers.31 However,
in obese pregnant women, supplementation of DHA and
EPA significantly reduces the inflammatory response in
maternal placental and adipose tissues, but plasma inflammatory markers do not show changes, except with respect to
a reduction of C-reactive protein concentration (p<0.05).14
Thus, the effects of FAs on the inflammation are not always
detectable in blood levels of inflammatory markers.
Likewise in our study, not all individual FFAs were associated with inflammatory biomarkers. It is generally believed
that the n-3 FAs have anti-inflammatory and SFAs have
proinflammatory properties.11 16 31 However, a recent study
suggested that differences in chain lengths of individual
SFAs had an opposite effect on inflammation.10 Currently,
there are insufficient data in human studies to predict of
which specific FAs will affect inflammatory status and how
the effect can be detected.9 15 30 32 We observed strong relationships, particularly with several FFAs representing monounsaturated, n3, n6, and saturated FFAs, suggesting the
unique impacts of FFAs on chronic inflammation during
pregnancy.
Finally, we did not find significant relationships between
FFAs (in %) and adiponectin. The association of adiponectin
to several SFA concentrations was dependent on maternal
BMI. Although adiponectin has a strong anti-inflammatory
property and the concentration is decreased in GDM,33 34 the
published results on its relationship with FFAs are mixed. A
report from Spain studied 17 FAs (without known lipid class
sources), and only found that palmitic acid and myristic acid
were negatively correlated with adiponectin in non-pregnant women (p=0.02 and p=0.007).35 A significant inverse
association between circulating adiponectin and plasma
non-esterified FA or palmitic acid levels was found during
an experimental elevation of intravascular triglyceride
lipolysis in healthy men.34 In contrast, acute lowering of total
FFA concentration pharmaceutically was associated with a
decrease in the adiponectin level.36 Further studies are also
needed to better understand the association of FFAs with
adiponectin in pregnancies.
Strengths and limitations
Strengths of our study are a well-characterized large
prospectively designed cohort including the measurements
of indices of IR/secretion, inflammatory biomarkers as well
as FFAs which have been validated and widely adopted in
experimental and epidemiologic studies.3 8 9 24 25 There are
some potential limitations. First, we included 25 women
diagnosed with GDM and also complicated with either
8

pre-eclampsia or preterm delivery because GDM is the focus
of this study. We could have performed a separate analysis for
GDM with and without pre-eclampsia or preterm delivery if
the sample size was larger. Second, circulating FFA composition has been considered as a biomarker of fat intake, but
the reports on their relationship have been inconsistent.37–40
We were unable to find strong relationships between plasma
FFAs and dietary fat intake by 24 hours’ recalls. Plasma FFA
levels are the end products of both exogenous (dietary fat
intake) and metabolism endogenously (lipolysis, lipogenesis and oxidation), it is not feasible for our epidemiologic
study to determine and distinguish the kinetics of fat metabolism. In addition, the time differences between blood
sample collection and the assessment of dietary intakes
could also contribute to the results. Lastly, we have used
diagnostic criteria for GDM from the American Diabetes
Association.22 By using the new criteria from the hyperglycemia and adverse pregnancy outcome (HAPO) can result
in a significantly increased number of women diagnosed
with GDM.41 42 The participants in our cohort were enrolled
prior to HAPO study, we did not obtain data of a 75 g OGTT
for all participants, and therefore, we are unable to detect
additional cases of GDM. In the current study, our main
focus is to examine the association of individual plasma
FFAs with the cardiometabolic markers including inflammation, IR and secretion in women of normal pregnancy and
with GDM. Our results suggested that individual FFAs have
unique impacts on inflammation and glucose metabolism
by mid-pregnancy.
In summary, our results found that individual FFAs are
differentially associated with IR/secretion and inflammatory biomarkers. The findings suggest that specific FFAs play
different roles in the regulation of glucose homeostasis in
normal pregnancy and in women prior to the diagnosis of
GDM. The effects are either direct or indirect depending
on the modulating inflammatory response. Thus, the recognition and modification (possibly by dietary essential FA
intake) of circulating FFA composition, especially the functional long-chain FFAs, is important for reducing the risk of
GDM and other pregnancy complications related to subclinical inflammation and IR.
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